Significant differences from respective TAT-GFP control are indicated as a,P<0
Significant differences from respective TAT-GFP control are indicated as a,P<0.05; b,P<0.01, and c,P<0.001. == 3.5. with comparable function. They regulate intracellular signalling such as the Raf-1/ERK[3]and PI3 kinase[4,5]cascades which are essential for survival and proliferation. Many studies have demonstrated a role for Ras in immune cells. In T lymphocytes activation of the T cell antigen receptor (TCR) causes quick accumulation of the active GTP-bound form of Ras[6], which in combination with other signals prospects to cytokine gene expression and clonal growth[79]. Recent reports have linked impaired Ras activation to induction of T cell anergy[10,11]highlighting the crucial role of this GTPase in determining the final end result following TCR activation. However, the role of Ras during the different stages of activation of main human T cells, or its role in animal models of inflammatory disease, has not been fully delineated. In the present study, we describe the generation and screening of novel protein inhibitors of Ras, which contain the Ras-binding domain name of Raf-1 (RBD), linked to the TAT protein transduction domain name (PTD). RBD specifically binds to Ras, while TAT PTD enables heterogeneous proteins and other biological brokers to enter cells[12,13]. We also test the effect of the Ras neutralizing mAb, Y13-259[14], when linked to TAT PTD. Our data show that these reagents readily enter cells and have a dual function; they diminish growth and increase apoptosis of lymphocytes stimulated in vitro, although with varying efficiency, suggesting a pro-survival role for Ras in activated T cells. Furthermore, using a model of T cell mediated inflammation, we show that lymphocytes activated physiologically in vivo are similarly susceptible to apoptosis when exposed to the TAT-coupled Ras inhibitors. == 2. Materials and methods == == 2.1. Cells, Abs, and reagents == Human PBMCs were isolated from heparinized venous blood by centrifugation over Ficoll-Hypaque (ICN Biomedicals, Aurora, OH) and cultured in RPMI 1640 medium made up of 5% FCS, 2 mMl-glutamine, 100 U/ml penicillin and 100 g/ml streptomycin. Splenocytes from C57Blk/6 mice were obtained by pushing spleens through a 70 m cell strainer (BD Biosciences, Bedford, MA) and mononuclear cells were purified by Ficoll-Hypaque. The human leukemic T cell collection Jurkat was maintained in the same medium as PBMCs and COS-7 cells were cultured in DMEM/10% FCS. All phosphor-specific antibodies were from Cell Signaling Technology (Beverly, MA), to Ras (Y13-259) from Santa Cruz Biotechnology (Santa Cruz, CA), and to anti-HA tag (mAb 12CA5) from Babco (Lakeside, CA). For activation of human and mouse T Toremifene cells, the following combination of mAbs were used; anti-human CD3 (clone HIT3a)/CD28 (clone CD28.2), and anti-mouse CD3 (clone 145-2C11)/CD28 (clone 37.51) from eBioscience (San Diego, CA). Dynabeads coated with sheep anti-rat IgG and sheep anti-mouse IgG were from Dynal (Oslo, Norway).PD098059and LY294002 were obtained from Calbiochem (La Jolla, CA) and farnesylthiosalicylic acid (FTS) from Biomol (Exeter, UK). == 2.2. Expression constructs and VPS15 purification of TAT-fusion proteins == The RBD domain name of human Raf-1 gene (amino acids 50130) was amplified with PCR using the forward primer 5-GGAGGTACCCCTTCTAAGACAAGCAACA-3 and the reverse primer 5-GAGCATGCTCACAGGAAATCTACTTGAAGT-3. For RBD-CRD (RCRD) (amino acids 50220 of Raf-1 which contains the cysteine-rich domain name adjacent to RBD) the same forward primer was used with the reverse primer 5-GAGCATGCTCAAGACTCTCGCATACGACG-3. PCR products were digested with KpnI/SphI and subcloned in frame into the corresponding sites of Toremifene the pRSET-TAT-HA vector. This vector, a kind gift from S. Dowdy (UCSD, CA), has Toremifene been explained previously and contains an 6xHis epitope for protein purification, the TAT PTD, and the HA tag[15]. TAT-RHA, which contains the HA2 fusogenic peptide from influenza haemmaglutinin (it is different from the HA tag) upstream of the RBD domain name, was constructed by commercially synthesizing the HA2-6xHis-TAT segment (GenScript, Piscataway, NJ). The HA2-6xHis-TAT was digested with XbaI/KpnI and inserted into the corresponding sites of pRSET-TAT-RBD to generate pRSET-TAT-RHA. DNA sequencing verified the accuracy of all expression constructs. Purification of TAT-fusion proteins Toremifene was performed under denaturing conditions using 8 M urea as previously explained[15,16]. The eluted proteins were adjusted to 10% glycerol, and stored at 70 C. To prevent aggregation proteins were kept at concentrations of 0.5 mg/ml. Y13-259 rat IgG1 was purified from culture supernatant using protein G-Sepharose (Amersham Biosciences, Uppsala, Sweden). Synthetic TAT peptide.